Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary reflects a mixed performance: stable financial metrics with slight declines in interest income and PIK income, but increased net investment income and net portfolio appreciation. The Q&A highlights stable portfolio yields, nonaccrual improvements, and a focus on capital scaling over share repurchases. However, management's avoidance of addressing broader economic uncertainties and lack of specific guidance on future dividend sustainability tempers positive sentiment. Overall, these factors balance out to a neutral outlook for the stock price over the next two weeks.
Fundings $44 million, including 3 new private equity sponsored investments totaling $34 million and $10 million of additional advances to existing portfolio companies. No year-over-year change mentioned.
Exits and Prepayments $46 million, declined relative to 2025. No specific reasons for the decline mentioned.
Interest Income $23.2 million, declined slightly by $700,000 or 2.9% year-over-year due to a 40 basis point decline in the weighted average yield on the interest-bearing portfolio.
Other Income $2.8 million, increased by $2.2 million due to prepayment fees and dividends.
Net Investment Income $11.8 million, increased by $574,000 due to higher net management fees and lower origination fee credits.
Net Portfolio Appreciation $4.2 million, driven by unrealized appreciation of 3 larger companies in the portfolio.
PIK Income $1.7 million, declined to 7.4% of interest income. No specific reasons for the decline mentioned.
Total Assets $925 million, consisting of $907 million in investments at fair value and $18 million in cash and other assets. Increased by $5.3 million quarter-over-quarter.
Liabilities $442 million, declined by $3 million quarter-over-quarter due to a decrease in LOC borrowings.
Net Assets $483 million, increased by $5.3 million quarter-over-quarter. NAV per share rose from $21.13 to $21.36.
Precision Manufacturing Demand: Strong demand for precision manufacturing businesses, driven by customers moving sourcing back to the U.S. or scaling to support defense-related backlogs.
Portfolio Management: Actively managing a healthy pipeline of investment opportunities to cover repayments and support modest asset growth.
Leverage Position: Maintained a conservative leverage position with net debt at 92% of NAV, leveraging a floating rate bank facility to mitigate short-term rate declines.
Investment Focus: Focus on private equity-backed lower middle market investment opportunities, particularly in precision manufacturing and defense-related sectors.
Interest Income Decline: Interest income for the period declined slightly to $23.2 million, driven by a 30 basis point decline in average SOFR rates.
Non-Earning Debt Investments: The company has three non-earning debt investments with a cost basis of $28.8 million, representing 1.6% of debt investments at fair value, which could impact overall portfolio returns.
Decline in PIK Income: PIK income for the quarter declined to $1.7 million, representing 7.4% of interest income, which could affect overall income levels.
Regulatory and Forward-Looking Risks: Forward-looking statements are subject to uncertainties and risks as outlined in SEC filings, which could materially impact future performance.
Weighted Average Yield Decline: The weighted average yield on the interest-bearing portfolio declined by 40 basis points to 11.8%, potentially impacting revenue generation.
Higher Expenses: Total expenses rose by $900,000 or 6.8%, driven by higher net management fees, which could pressure net income.
Portfolio Growth and Investment Outlook: The company expects modest asset growth supported by a healthy pipeline of investment opportunities. This includes strong demand for precision manufacturing businesses, particularly those focusing on reshoring and defense-related backlogs.
Leverage and Borrowing Capacity: Gladstone Capital maintains a conservative leverage position with net debt at 92% of NAV. The company plans to continue leveraging its floating rate bank facility to support floating rate assets, mitigating the impact of short-term rate declines. The current line of credit facility totals $365 million, with over $150 million in borrowing availability to support near-term investment activities.
Healthcare Industry Concentration: The company anticipates a further decline in healthcare-related industry concentration in the short term due to pending exits.
Monthly Distributions: Monthly distributions for May and June will be $0.15 per common share, which is an annual run rate of $1.80 per share.
Dividend Yield: At the current distribution rate for common stock and with a common stock price at about $19.21 per share, the distribution run rate is now producing a yield of about 9.4%.
Dividend Coverage: Earnings performance bolstered by prepayment fees and portfolio distributions more than cover the current shareholder dividends.
The earnings call summary reflects a mixed performance: stable financial metrics with slight declines in interest income and PIK income, but increased net investment income and net portfolio appreciation. The Q&A highlights stable portfolio yields, nonaccrual improvements, and a focus on capital scaling over share repurchases. However, management's avoidance of addressing broader economic uncertainties and lack of specific guidance on future dividend sustainability tempers positive sentiment. Overall, these factors balance out to a neutral outlook for the stock price over the next two weeks.
The earnings call reveals mixed signals: while there are positive elements like a healthy deal pipeline and strategic debt refinancing, concerns arise from unrealized losses and the impact of government shutdowns. The Q&A session highlights cautious management responses and uncertainties in AI and data center trends. Despite some positive elements, the overall sentiment is tempered by challenges, leading to a neutral outlook.
The earnings call presents mixed signals: strong portfolio growth and high ROE are offset by increased financing costs and net realized losses. The Q&A reveals optimism about pipeline growth and asset quality, but unclear responses about dividend cuts and portfolio challenges raise concerns. The company's strategic focus on growth and leverage management is positive, but the lack of specific guidance and dividend reduction temper market enthusiasm. Given these factors, the stock price reaction is likely to be neutral.
The earnings call reveals a mixed picture: While the company maintains a healthy pipeline and conservative leverage, there are concerns about economic uncertainties and elevated leverage ratios. The Q&A section highlights management's cautious stance on future M&A activity and lack of clarity on addressing upcoming debt maturities. Despite a slight increase in portfolio yield, net assets declined. These factors, combined with a flat net investment income, suggest limited short-term stock price movement, resulting in a neutral sentiment rating.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.